Cochrane Abstracts
Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Weekly Versus Tri‐weekly Paclitaxel With Carboplatin for First‐line Treatment in Women With Epithelial Ovarian Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431018/all/Weekly_versus_tri‐weekly_paclitaxel_with_carboplatin_for_first‐line_treatment_in_women_with_epithelial_ovarian_cancer.
Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431018/all/Weekly_versus_tri‐weekly_paclitaxel_with_carboplatin_for_first‐line_treatment_in_women_with_epithelial_ovarian_cancer. Accessed March 17, 2025.
Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431018/all/Weekly_versus_tri‐weekly_paclitaxel_with_carboplatin_for_first‐line_treatment_in_women_with_epithelial_ovarian_cancer
Weekly Versus Tri‐weekly Paclitaxel With Carboplatin for First‐line Treatment in Women With Epithelial Ovarian Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 17]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431018/all/Weekly_versus_tri‐weekly_paclitaxel_with_carboplatin_for_first‐line_treatment_in_women_with_epithelial_ovarian_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer
ID - 431018
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431018/all/Weekly_versus_tri‐weekly_paclitaxel_with_carboplatin_for_first‐line_treatment_in_women_with_epithelial_ovarian_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
